Opening book details…
Can I read Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients on EtoBox?
Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients by Teng, Wei (author);Liu, Yen-Chun (author);Jeng, Wen-Juei (author);Su, Chien-Wei (author) is a Medicine article available to read on EtoBox.
What is Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients about?
## Simple Summary Hepatocellular carcinoma (HCC) recurrence is the major obstacle concerning patients’ survival. Tertiary prevention by antiviral therapies could reduce HCC recurrence rate in both chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infected patients. In chronic hepatitis B (CHB) patients, nucleos(t)ide analogues (Nuc) provide a more effective HCC tertiary prevention effect than an interferon (IFN)-based regimen. In chronic hepatitis C (CHC) patients, the tertiary prevention effect by direct acting antiviral agents (DAAs) was reported non-inferior to that by IFN-based therapy. Chronic hepatitis C patients left untreated had the worst survival benefit as well as shorted recurrence-free interval than those treated by either type of antiviral regimen. Although the risk of HCC recurrence could only be decreased but not diminished by antiviral therapies due to host and microenvironmental factors beyond virus infection, antiviral therapy helps to preserve and improve liver function which makes multi-modality anticancer treatment feasible to improve survival. ## Abstract Hepatocellular carcinoma (HCC) ranks as a leading cause of common cancer and cancer-related deat
Who reads Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Teng, Wei (author);Liu, Yen-Chun (author);Jeng, Wen-Juei (author);Su, Chien-Wei (author)
- Publisher
- MDPI AG
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)